Immunic (NASDAQ:IMUX) Downgraded by StockNews.com to “Sell”

StockNews.com downgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note published on Thursday morning.

Other research analysts have also recently issued research reports about the company. Brookline Capital Management reiterated a buy rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, April 5th. Piper Sandler reiterated an overweight rating and issued a $28.00 price objective on shares of Immunic in a research note on Tuesday, July 16th.

Immunic Stock Performance

Shares of IMUX opened at $1.39 on Thursday. The firm has a market cap of $125.21 million, a P/E ratio of -0.76 and a beta of 1.77. Immunic has a 52 week low of $0.95 and a 52 week high of $2.45. The firm’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.27.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. As a group, equities analysts forecast that Immunic will post -0.94 earnings per share for the current year.

Institutional Trading of Immunic

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Immunic in the first quarter worth $25,000. Summit Trail Advisors LLC bought a new position in Immunic in the 1st quarter valued at about $25,000. Sierra Summit Advisors LLC bought a new position in Immunic in the 4th quarter valued at about $487,000. Ikarian Capital LLC raised its position in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares in the last quarter. Finally, Gratus Capital LLC lifted its holdings in shares of Immunic by 15.1% during the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after acquiring an additional 254,999 shares during the period. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.